• Diagnosis​ ​Info​ ​and​ ​General​ ​Questions

  Approval of Exondys 51 to Treat DMD Opposed by European Medicines Agency

  Posted by MD forums Moderator on March 29, 2019 at 8:11 am

  The Committee for Medicinal Products for Human Use (CHMP) — part of the European Medicines Agency (EMA) — is recommending against Exondys 51 (eteplirsen) as a therapy for Duchenne muscular dystrophy (DMD), Sarepta Therapeutics announced. Click here to find out why.

  Do you agree with the CMPH’s position?

  replied 6 years, 1 month ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply